Bristol-Myers Squibb Company
Carbohydrate content of CTLA4 molecules
Last updated:
Abstract:
The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.
Status:
Grant
Type:
Utility
Filling date:
24 Jul 2018
Issue date:
1 Dec 2020